Knowledge, attitudes, and behaviors related to the fentanyl-adulterated drug supply among people who use drugs in Oregon
- PMID: 35932759
- PMCID: PMC10635798
- DOI: 10.1016/j.jsat.2022.108849
Knowledge, attitudes, and behaviors related to the fentanyl-adulterated drug supply among people who use drugs in Oregon
Abstract
Introduction: Nonpharmaceutical fentanyl has reconfigured the U.S. illicit drug market, contributing to a drastic increase in overdose drug deaths. While illicit fentanyl has subsumed the drug supply in the Northeast and Midwest, it has more recently reached the West. For this study, we explored knowledge, attitudes, and behaviors among people who use drugs in Oregon in the context of the emergence of fentanyl in the drug supply.
Methods: We conducted in-depth interviews by phone with 34 people who use drugs in Oregon from May to June 2021. We used thematic analysis to analyze transcripts and construct themes.
Results: People who use drugs knew about fentanyl, expressed doubt that fentanyl could be found in methamphetamine; believed those who were younger or less experienced were at higher risk for harm; and received information about fentanyl from drug dealers, syringe service programs, or peers (other people who use drugs). Preference for fentanyl's presence in drugs like heroin or methamphetamine was mixed. Some felt that their preference was irrelevant since fentanyl was unavoidable. Participants reported engaging in harm reduction practices, including communicating about fentanyl with dealers and peers, testing for fentanyl, using smaller quantities of drugs, switching from injecting to smoking, and using naloxone.
Conclusion: People who use drugs are responding to the rise of fentanyl on the West Coast and are concerned about the increasing uncertainty and hazards of the drug supply. They are willing and motivated to adopt harm reduction behaviors. Harm reduction promotion from syringe service programs and public health agencies is essential to reduce injury and death from nonpharmaceutical fentanyl.
Keywords: Fentanyl; Harm reduction; Methamphetamine; Opioids; Overdose; Qualitative research; Substance use.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest:
Andrew Seaman has received investigator-initiated research support from Gilead and Merck Pharmaceuticals.
References
-
- Armenian P, Vo KT, Barr-Walker J, & Lynch KL (2018). Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology, 134, 121–132. - PubMed
-
- Baker R, Leichtling G, Hildebran C, Pinela C, Waddell E, Sidlow C, Leahy JM, & Korthuis PT (2021). “Like Yin and Yang”: Perceptions of Methamphetamine Benefits and Consequences Among People Who Use Opioids in Rural Communities. Journal of Addiction Medicine, 15(1), 34–39. 10.1097/ADM.0000000000000669 - DOI - PMC - PubMed
-
- Banta-Green C, & Williams J. (2021). Dramatic increases in opioid overdose deaths due to fentanyl among young people in Washington State. Seattle, WA: Addictions, Drug & Alcohol Institute, University of Washington.
-
- Bardwell G, Boyd J, Tupper KW, & Kerr T. (2019). “We don’t got that kind of time, man. We’re trying to get high!”: Exploring potential use of drug checking technologies among structurally vulnerable people who use drugs. International Journal of Drug Policy, 71, 125–132. 10.1016/j.drugpo.2019.06.018 - DOI - PMC - PubMed
-
- Bolinski RS, Walters S, Salisbury-Afshar E, Ouellet LJ, Jenkins WD, Almirol E, Van Ham B, Fletcher S, Johnson C, Schneider JA, Ompad D, & Pho MT (2022). The Impact of the COVID-19 Pandemic on Drug Use Behaviors, Fentanyl Exposure, and Harm Reduction Service Support among People Who Use Drugs in Rural Settings. Int J Environ Res Public Health, 19(4). 10.3390/ijerph19042230 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical